407 related articles for article (PubMed ID: 15457184)
41. Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.
Mohamedbhai SG; Edwards N; Morris EC; Mackinnon S; Thomson KJ; Peggs KS
Br J Haematol; 2012 Feb; 156(4):516-22. PubMed ID: 22171699
[TBL] [Abstract][Full Text] [Related]
42. Simultaneous cord blood transplantation of ex vivo expanded together with non-expanded cells for high risk leukemia.
Kögler G; Nürnberger W; Fischer J; Niehues T; Somville T; Göbel U; Wernet P
Bone Marrow Transplant; 1999 Aug; 24(4):397-403. PubMed ID: 10467329
[TBL] [Abstract][Full Text] [Related]
43. Use of natural killer cells in hematopoetic stem cell transplantation.
Passweg JR; Stern M; Koehl U; Uharek L; Tichelli A
Bone Marrow Transplant; 2005 Apr; 35(7):637-43. PubMed ID: 15654351
[TBL] [Abstract][Full Text] [Related]
44. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies.
Chang YJ; Zhao XY; Huang XJ
Biol Blood Marrow Transplant; 2008 Mar; 14(3):323-34. PubMed ID: 18275899
[TBL] [Abstract][Full Text] [Related]
45. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT.
Urbano-Ispizua A; Solano C; Brunet S; de la Rubia J; Odriozola J; Zuazu J; Figuera A; Caballero D; Martínez C; García J; Sanz G; Torrabadella M; Alegre A; Pérez-Oteiza J; Jurado M; Oyonarte S; Sierra J; García-Conde J; Rozman C
Bone Marrow Transplant; 1998 Sep; 22(6):519-25. PubMed ID: 9758337
[TBL] [Abstract][Full Text] [Related]
46. [Quantitative analysis of donor chimerism in adoptive immunotherapy following allogeneic hematopoietic stem cell transplantation].
Tang XW; Wu DP; Sun AN; Zhu ZL; Chang WR; Ruan CG
Zhonghua Nei Ke Za Zhi; 2006 May; 45(5):359-62. PubMed ID: 16780733
[TBL] [Abstract][Full Text] [Related]
47. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
48. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.
Shah NN; Baird K; Delbrook CP; Fleisher TA; Kohler ME; Rampertaap S; Lemberg K; Hurley CK; Kleiner DE; Merchant MS; Pittaluga S; Sabatino M; Stroncek DF; Wayne AS; Zhang H; Fry TJ; Mackall CL
Blood; 2015 Jan; 125(5):784-92. PubMed ID: 25452614
[TBL] [Abstract][Full Text] [Related]
49. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
[TBL] [Abstract][Full Text] [Related]
50. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
Ruggeri L; Capanni M; Urbani E; Perruccio K; Shlomchik WD; Tosti A; Posati S; Rogaia D; Frassoni F; Aversa F; Martelli MF; Velardi A
Science; 2002 Mar; 295(5562):2097-100. PubMed ID: 11896281
[TBL] [Abstract][Full Text] [Related]
52. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
53. Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children.
Lang P; Pfeiffer M; Handgretinger R; Schumm M; Demirdelen B; Stanojevic S; Klingebiel T; Köhl U; Kuci S; Niethammer D
Bone Marrow Transplant; 2002 Mar; 29(6):497-502. PubMed ID: 11960269
[TBL] [Abstract][Full Text] [Related]
54. CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study.
Alyea EP; Canning C; Neuberg D; Daley H; Houde H; Giralt S; Champlin R; Atkinson K; Soiffer RJ
Bone Marrow Transplant; 2004 Jul; 34(2):123-8. PubMed ID: 15133487
[TBL] [Abstract][Full Text] [Related]
55. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation.
Breuer S; Preuner S; Fritsch G; Daxberger H; Koenig M; Poetschger U; Lawitschka A; Peters C; Mann G; Lion T; Matthes-Martin S
Leukemia; 2012 Mar; 26(3):509-19. PubMed ID: 21926962
[TBL] [Abstract][Full Text] [Related]
56. Donor Chimerism of B Cells and Nature Killer Cells Provides Useful Information to Predict Hematologic Relapse following Allogeneic Hematopoietic Stem Cell Transplantation.
Jiang Y; Wan L; Qin Y; Wang X; Yan S; Xie K; Wang C
PLoS One; 2015; 10(7):e0133671. PubMed ID: 26226104
[TBL] [Abstract][Full Text] [Related]
57. Loss of mismatched HLA in myeloid/NK cell precursor acute leukemia relapse after T cell-replete haploidentical hematopoietic stem cell transplantation.
Kobayashi S; Kikuta A; Ito M; Sano H; Mochizuki K; Akaihata M; Waragai T; Ohara Y; Ogawa C; Ono S; Ohto H; Hosoya M
Pediatr Blood Cancer; 2014 Oct; 61(10):1880-2. PubMed ID: 24464971
[TBL] [Abstract][Full Text] [Related]
58. The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation.
Karasu GT; Yesilipek MA; Karauzum SB; Uygun V; Manguoglu E; Kupesiz A; Hazar V
Pediatr Blood Cancer; 2012 Mar; 58(3):453-8. PubMed ID: 21990066
[TBL] [Abstract][Full Text] [Related]
59. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Björkström NK; Söderdahl G; Cederlund K; Kimby E; Aschan J; Ringdén O; Ljunggren HG; Dilber MS
Immunotherapy; 2009 Sep; 1(5):753-64. PubMed ID: 20636021
[TBL] [Abstract][Full Text] [Related]
60. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation.
Bishop MR; Steinberg SM; Gress RE; Hardy NM; Marchigiani D; Kasten-Sportes C; Dean R; Pavletic SZ; Gea-Banacloche J; Castro K; Hakim F; Krumlauf M; Read EJ; Carter C; Leitman SF; Fowler DH
Br J Haematol; 2004 Sep; 126(6):837-43. PubMed ID: 15352988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
